Fig. 5

EFS by MFC-MRD status at TP1 and TP2, stratifying risks per the C-HUANAN-AML 15 protocol.According to MFC-MRD levels, patients were stratified into two MFC-MRD-based groups (MRD < 0.1%; MRD ≥ 0.1%). EFS according to MFC-MRD at TP1 in a separate analysis of LR (a), IR (b) and HR (c) patients. EFS according to MFC-MRD at TP2 in a separate analysis of LR (d), IR (e) and HR (f) patients. EFS, event-free survival; MFC, multiparametric flow cytometry; MRD, minimal residual disease; TP1, after the first induction course; TP2, at the end of the second induction course (before start of consolidation)